Literature DB >> 1604386

Tuberculosis in the 1990's: resurgence, regimens, and resources.

R E Pust1.   

Abstract

Physicians in the United States must maintain vigilance for the 25,000 annual new cases of tuberculosis, concentrated in the elderly, in immigrants, in migrant and minority populations, and in immunosuppressed patients. Tuberculosis rates in the South remain above the national average. Physicians diagnosing tuberculosis may also treat the disease, working with health departments, which can assist with drugs, follow-up tests, and contact investigation. Powerful short-course regimens have been standard treatments since 1986. The preferred combination is isoniazid, rifampin, and pyrazinamide daily for 2 months, followed by isoniazid and rifampin for 4 more months. A 9-month regimen of isoniazid and rifampin is equally effective. Supplementation or extension of these regimens is mandatory when drug resistance or immunosuppression, respectively, is likely. Isoniazid prophylaxis for 6 to 12 months continues to be a vital but often neglected preventive measure for those infected with Mycobacterium tuberculosis, but without active disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1604386

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Bilateral parotid gland tuberculosis.

Authors:  Alper Nabi Erkan; Ozcan Cakmak; Fazilet Kayaselçuk; Fatih Köksal; Levent Ozlüoglu
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-02-11       Impact factor: 2.503

2.  Clinical differences between pulmonary and extrapulmonary tuberculosis: a 5-year retrospective study.

Authors:  S J Antony; V Harrell; J D Christie; H G Adams; R L Rumley
Journal:  J Natl Med Assoc       Date:  1995-03       Impact factor: 1.798

3.  Nasal deformity due to tuberculous chondritis.

Authors:  Soo-Youn Moon; Jeong-A Lee; Mi Kyong Joung; Doo Ryeon Chung; Jae-Hoon Song; Kyong Ran Peck
Journal:  Clin Exp Otorhinolaryngol       Date:  2014-08-01       Impact factor: 3.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.